NO
ALXN

Ninety One’s Alexion Pharmaceuticals ALXN Stock Holding History

Ninety One’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,753
Closed -$958K – 114
2020
Q1 		$958K Buy
10,753
+573
+6% +$56.2K 0.47% 47
2019
Q4 		$995K Hold
10,180
– – 0.56% 68
2019
Q3 		$995K Sell
10,180
-268
-3% -$30.2K 0.56% 68
2019
Q2 		$1.34M Buy
10,448
+1,149
+12% +$148K 0.75% 53
2019
Q1 		$1.25M Buy
9,299
+242
+3% +$30.1K 0.66% 52
2018
Q4 		$901K Sell
9,057
-18,026
-67% -$2.13M 0.53% 62
2018
Q3 		$3.78M Hold
27,083
– – 0.62% 46
2018
Q2 		$3.37M Buy
27,083
+17,890
+195% +$2.09M 0.46% 61
2018
Q1 		$1.02M Hold
9,193
– – 0.48% 53
2017
Q4 		$1.11M Buy
+9,193
New +$1.12M 0.55% 40

Other funds holding ALXN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ninety One's ALXN Position: Q2 2020 in Review

Ninety One sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 10,753 shares — an estimated $958K sold.

Ninety One first reported a position in ALXN in Q4 2017 and held it in 10 quarters. The position peaked at $3.78M in Q3 2018. 706 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Ninety One reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Ninety One sold 10,753 Alexion Pharmaceuticals shares in Q2 2020, an estimated $958K.
  • Ninety One first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 10 quarters.
  • Ninety One's Alexion Pharmaceuticals position peaked at $3.78M in Q3 2018.
  • 706 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Ninety One's 13F filing for Q2 2020, filed 13 Aug 2020.